Clinical Trial Detail

NCT ID NCT00997334
Title Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors David M. Jackman, MD
Indications

lung non-small cell carcinoma

Therapies

Erlotinib

Age Groups: adult

No variant requirements are available.